Novo Nordisk plans to invest almost 1 billion Danish kroner (134 million euros) in a new biologics manufacturing facility at its Kalundborg site, the largest in the group’s production network. The new capacity will be used to manufacture biopharmaceuticals such as Factor VIIa, used in Novo’s NovoSeven drug for haemophilia, as well as growth hormone and other biologic medicines. The factory is expected to create 120–150 new jobs in Kalundborg over the next three years, adding to its current tally of around 2,600. Kalundborg is also the primary manufacturing site in the Novo network for insulin production, as well as for filling, finishing and packaging insulin drugs.
